Connor Clark & Lunn Investment Management Ltd. Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Connor Clark & Lunn Investment Management Ltd. lowered its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,060 shares of the company's stock after selling 38,263 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.12% of Tarsus Pharmaceuticals worth $1,548,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after acquiring an additional 1,530 shares in the last quarter. Dark Forest Capital Management LP bought a new position in Tarsus Pharmaceuticals in the second quarter worth $202,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after buying an additional 3,379 shares in the last quarter. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock traded up $1.18 during mid-day trading on Wednesday, hitting $50.84. The stock had a trading volume of 486,400 shares, compared to its average volume of 724,501. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm's 50 day moving average is $40.00 and its 200 day moving average is $33.06. Tarsus Pharmaceuticals, Inc. has a one year low of $15.60 and a one year high of $52.99.

Analyst Ratings Changes

Several research firms recently commented on TARS. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th. Finally, William Blair upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $54.20.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.